VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agentsDavid F. Stojdl, John C. Bell, Brian D. Lichty et al.|Cancer Cell|2003Cited by 850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virusDavid F. Stojdl, John C. Bell, Brian D. Lichty et al.|Nature Medicine|2000Cited by 816
Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood FlowCaroline J. Breitbach, John C. Bell, Theresa Falls et al.|Molecular Therapy|2007Cited by 277
Characterization of Transgenic Mice with Targeted Disruption of the Catalytic Domain of the Double-stranded RNA-dependent Protein Kinase, PKRN. B. Abraham, John C. Bell, David F. Stojdl et al.|Journal of Biological Chemistry|1999Cited by 230
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysisThi Lien-Anh Nguyên, John Hiscott, Hesham Abdelbary et al.|Proceedings of the National Academy of Sciences|2008Cited by 182